Literature DB >> 2335602

Monitoring liver tumor therapy with [18F]FDG positron emission tomography.

Y Nagata1, K Yamamoto, M Hiraoka, M Abe, M Takahashi, K Akuta, Y Nishimura, S Jo, S Masunaga, S Kubo.   

Abstract

Positron emission tomography (PET) with [18F]-2-flurodeoxy-glucose (FDG) can be utilized as a functional imaging modality for monitoring liver tumor therapy. We report three cases in which PET-FDG was more useful for this purpose than other imaging methods and tumor markers.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2335602

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN： 0363-8715            Impact factor:   1.826


  10 in total

Review 1.  18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies.

Authors:  B B Chin; R L Wahl
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

2.  Cancer treatment monitoring with fluorine-18 2-fluoro-2-deoxy-D-glucose and positron emission tomography: frustration or future.

Authors:  H Minn; R Paul
Journal:  Eur J Nucl Med       Date:  1992

3.  Update of PET and PET/CT for hepatobiliary and pancreatic malignancies.

Authors:  Dominique Delbeke; William H Martin
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

4.  Dynamic analysis of GI absorption and hepatic distribution processes of telmisartan in rats using positron emission tomography.

Authors:  Makoto Kataoka; Tadayuki Takashima; Tomotaka Shingaki; Yoshinobu Hashidzume; Yumiko Katayama; Yasuhiro Wada; Hiroyuki Oh; Yoshie Masaoka; Shinji Sakuma; Yuichi Sugiyama; Shinji Yamashita; Yasuyoshi Watanabe
Journal:  Pharm Res       Date:  2012-05-23       Impact factor: 4.200

5.  A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma.

Authors:  Y Ichiya; Y Kuwabara; M Sasaki; T Yoshida; J Omagari; Y Akashi; A Kawashima; T Fukumura; K Masuda
Journal:  Ann Nucl Med       Date:  1996-05       Impact factor: 2.668

Review 6.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

7.  Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.

Authors:  I C Smith; K N Ogston; P Whitford; F W Smith; P Sharp; M Norton; I D Miller; A K Ah-See; S D Heys; J A Jibril; O Eremin
Journal:  Ann Surg       Date:  1998-08       Impact factor: 12.969

8.  Evaluation of the treatment response of lung cancer with positron emission tomography and L-[methyl-11C]methionine: a preliminary study.

Authors:  K Kubota; S Yamada; K Ishiwata; M Ito; T Fujiwara; H Fukuda; M Tada; T Ido
Journal:  Eur J Nucl Med       Date:  1993-06

9.  FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model.

Authors:  Hee Sun Park; Jin Wook Chung; Hwan Jun Jae; Young Il Kim; Kyu Ri Son; Min Jong Lee; Jae Hyung Park; Won Jun Kang; Jung Hwan Yoon; Hesson Chung; Kichang Lee
Journal:  Korean J Radiol       Date:  2007 May-Jun       Impact factor: 3.500

10.  [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study.

Authors:  Bernd Gagel; Patrick Reinartz; Cengiz Demirel; Hans J Kaiser; Michael Zimny; Marc Piroth; Michael Pinkawa; Sven Stanzel; Branka Asadpour; Kurt Hamacher; Heinz H Coenen; Ulrich Buell; Michael J Eble
Journal:  BMC Cancer       Date:  2006-03-04       Impact factor: 4.430
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.